VEGFA and neoplasm: Anti-VEGF therapies mitigate VEGF-induced immunosuppression in both the tumor and its surrounding microenvironment [7,8] and might amplify anti-PD-L1 efficiency due to the reversion of VEGF-mediated immunosuppression and promotion of T-cell infiltration in tumors [9,10,11].